読み込み中
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
前日終値
$27.11
+$1.23 · +4.75%
日中の時刻はETです。市場データは遅延する場合があります。
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
日中レンジ
現在 $27.11
52週レンジ
現在 $27.11
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
2
著しい割高
センチメント
58
まちまち
リスク
66
高リスク
モメンタム
51
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
日中レンジ
現在 $27.11
52週レンジ
現在 $27.11
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|
| 売上高 | — | 1.68億 USD | — | — |
| 売上原価 | 240.3万 USD | — | — | — |
| 粗利益 | −240.3万 USD | 1.68億 USD | — | — |
| 研究開発 | 1.08億 USD | 8349.6万 USD | 7394.5万 USD | 8819.2万 USD |
| 販売・一般管理 | 3445.1万 USD | 2641.8万 USD | 2460.6万 USD | 2283.4万 USD |
| 営業費用 | 1.4億 USD | 1.1億 USD | 9855.1万 USD | 1.11億 USD |
| 受取利息 | 1177.9万 USD | 465.4万 USD | 196.6万 USD | 202.8万 USD |
| 減価償却費と償却費 | 240.3万 USD | 329.7万 USD | 408.9万 USD | 382万 USD |
| 営業利益 | −1.43億 USD | 5758.6万 USD | −9855.1万 USD | −1.11億 USD |
| 純利益 | −1.31億 USD | 5223.1万 USD | −1億 USD | −1.15億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI3751.66万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM2404.63万0.03%787.4億 USD0.19%$278.94+0.49%
State Street SPDR S&P Pharmaceuticals ETFXPH878.6万1.90%4.62億 USD0.35%$64.65+1.60%
Vanguard Extended Market ETFVXF875.11万0.01%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO711.74万0.05%139.17億 USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB687.2万0.07%108.2億 USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO538.74万0.03%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA507.98万0.02%218.24億 USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
